Loading clinical trials...
Loading clinical trials...
Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions (DLI) From 3-5/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (ASCT)
Conditions
Interventions
NK-CD56
Locations
1
United States
Duke University Health Systems
Durham, North Carolina, United States
Start Date
April 1, 2005
Primary Completion Date
April 1, 2013
Completion Date
November 1, 2013
Last Updated
June 12, 2014
NCT07388563
NCT06337318
NCT06263491
NCT05529069
NCT05139017
NCT06189391
Lead Sponsor
David Rizzieri, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions